Aye Chen

Title: Aye Chen: Innovator in Chimeric Antigen Receptors

Introduction

Aye Chen is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). With a total of 4 patents, her work has the potential to revolutionize cancer treatment.

Latest Patents

Aye Chen's latest patents include innovative technologies such as chimeric antigen receptors specific for B-cell maturation antigen. These receptors comprise BCMA-binding molecules, including anti-BCMA antibodies and their fragments. The patents also detail genetically engineered cells expressing these CARs, which can be utilized in adoptive cell therapy. Another notable patent focuses on antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1 (ROR1). This work includes human antibodies specific for ROR1 and related genetically engineered cells, further advancing the field of adoptive cell therapy.

Career Highlights

Throughout her career, Aye Chen has worked with esteemed organizations such as Juno Therapeutics and Memorial Sloan Kettering Cancer Center. Her experience in these leading research institutions has allowed her to contribute significantly to the development of cutting-edge therapies.

Collaborations

Aye Chen has collaborated with notable professionals in her field, including Rupesh Amin and Collin Hauskins. These partnerships have fostered innovation and advancement in her research endeavors.

Conclusion

Aye Chen's contributions to the field of immunotherapy through her patents and collaborations highlight her as a leading inventor in the development of chimeric antigen receptors. Her work continues to pave the way for new therapeutic approaches in cancer treatment.